| 0.4141 -0.009 (-2.15%) | 12-05 15:58 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.62  |
1-year : | 0.72 |
| Resists | First : | 0.53 |
Second : | 0.62 |
| Pivot price | 0.4 |
|||
| Supports | First : | 0.38 |
Second : | 0.29 |
| MAs | MA(5) : | 0.43 |
MA(20) : | 0.4  |
| MA(100) : | 0.73 |
MA(250) : | 1.14 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 61 |
D(3) : | 64.5 |
| RSI | RSI(14): 44.4 |
|||
| 52-week | High : | 3.02 | Low : | 0.29 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ INM ] has closed below upper band by 42.1%. Bollinger Bands are 56.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.43 - 0.43 | 0.43 - 0.44 |
| Low: | 0.4 - 0.4 | 0.4 - 0.4 |
| Close: | 0.41 - 0.42 | 0.42 - 0.42 |
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Thu, 30 Nov 2023
How Will the Market React to InMed Pharmaceuticals Inc (INM) Stock Getting a Bullish Rating - InvestorsObserver
Thu, 30 Nov 2023
Inmed's INM-089 improves retinal function in in vivo preclinical AMD disease model - BioWorld Online
Wed, 29 Nov 2023
InMed Expands its Pharmaceutical Pipeline with INM-089 targeting the treatment of Age-Related Macular Degeneration - Yahoo Finance
Wed, 08 Nov 2023
InMed Pharmaceuticals files to sell 12.57M shares for holders (NASDAQ:INM) - Seeking Alpha
Thu, 26 Oct 2023
InMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option ... - Yahoo Finance
Thu, 26 Oct 2023
Is it Time to Dump InMed Pharmaceuticals Inc (INM) Stock After it Has Gained 16.67% in a Week? - InvestorsObserver
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 7 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 3 (%) |
| Shares Short | 5 (K) |
| Shares Short P.Month | 4 (K) |
| EPS | 0.05 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.88 |
| Profit Margin | -147.9 % |
| Operating Margin | -291 % |
| Return on Assets (ttm) | -36.9 % |
| Return on Equity (ttm) | -67.8 % |
| Qtrly Rev. Growth | 181.1 % |
| Gross Profit (p.s.) | 0.21 |
| Sales Per Share | 0.71 |
| EBITDA (p.s.) | -1.11 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | 8.34 |
| PEG Ratio | 0 |
| Price to Book value | 0.14 |
| Price to Sales | 0.58 |
| Price to Cash Flow | -0.39 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|